

Fig. 4.—Methyl orange bound by DnEa and deaminated Ea fractions—key to chart: \diamond DnEa 105, \blacklozenge DnEa 105 Deam-SH, \square 5A, \times 5A Dn, $+$ 8B Dn.

in Table IV. Here, too, a definite difference is shown between acid DnEa and heat DnEa on the one hand, and an A fraction on the other. In 1.5 *N* NaCl solution the A fraction remains soluble whereas the DnEa preparations precipitate to the extent of 60%. This would indicate that the A fraction does not exist in a form as fully extended or as subject to aggregation as the other DnEa preparations, in accord with the nitroprusside tests and the particle weights. In its salt sensitivity, also, fraction 5ADn appeared to be more unfolded or aggregated than 5A. Whereas 5A was opalescent in 2.0 *M* NaCl, 5ADn precipitated to the extent of 24%. Acid denatured 8B showed

less tendency to aggregate than DnEa, in agreement with the viscosity data.

TABLE IV
EFFECT OF SODIUM CHLORIDE SOLUTIONS ON VARIOUS DENATURED PREPARATIONS. PER CENT. PROTEIN PRECIPITATED, 1 HR., 37°

	0.25 <i>M</i>	0.5 <i>M</i>	1.0 <i>M</i>	1.5 <i>M</i>	2.0 <i>M</i>	2.5 <i>M</i>
5A	<i>a</i>	<i>a</i>	<i>a</i>	<i>a</i>	<i>b</i>	63
5A Dn	<i>a</i>	<i>a</i>	<i>a</i>	<i>b</i>	24 ^c	76
Acid DnEa 105	<i>a</i>	<i>b</i>	<i>b</i>	57	72	99
8B Dn	<i>a</i>	<i>a</i>	<i>b</i>	31 ^c	69	88
Heat Dn 27	<i>b</i>	<i>b</i>	63	88	94	98

^a Clear solution. ^b Opalescent solution. ^c Supernatant opalescent after centrifugation.

9. **Binding of Methyl Orange.**—The extent of binding of the anion of methyl orange by approximately 0.2% protein solutions was measured at *pH* 6.8 by differential dialysis.³⁶ The samples were dialyzed against dye solutions ranging in concentration from 0.165×10^{-5} to 8.40×10^{-5} *M*. The results are summarized in Fig. 4. Neither Ea nor 8B bound dye, but DnEa did, in agreement with results and statements of others.³⁷

When acid DnEa is deaminated, it has a reduced binding ability similar to that of the A and ADn preparations. 8BDn, which can be considered in a sense "isomeric" with deaminated DnEa, binds less than DnEa and more than its deaminated form. It is difficult to decide what part in these relationships is played by the decrease in cationic nitrogen and what part is due to differences in molecular configuration.

(36) I. M. Klotz, F. M. Walker and R. B. Piven, *THIS JOURNAL*, **68**, 1486 (1946).

(37) I. M. Klotz and J. M. Urquhart, *ibid.*, **71**, 1597 (1949).
NEW YORK, N. Y.

RECEIVED JULY 11, 1950

[CONTRIBUTION FROM THE DEPARTMENTS OF BIOCHEMISTRY AND MEDICINE, COLLEGE OF PHYSICIANS AND SURGEONS COLUMBIA UNIVERSITY]

The Deamination of Crystalline Egg Albumin.^{1,2} III. Quantitative Immunochemical Studies on Crystalline Egg Albumin and its Denatured and Deaminated Derivatives

BY PAUL H. MAURER AND MICHAEL HEIDELBERGER

The serological specificity of Ea is not influenced by the removal of about one-third of the free $-\text{NH}_2$ groups when the protein remains undenatured. In the denatured form, which shows a specificity different from that of Ea, removal of up to ca. 60% of $-\text{NH}_2$ from DnEa or A resulted in a scarcely significant decrease in the nitrogen precipitated from their homologous antisera. Changes in immunological specificity of Ea, DnEa, and fractions A and B due to physical aggregation or change of $-\text{S}-\text{S}-$ to $-\text{SH}$ linkages are relatively minor. The quantitative immunochemical data supplement information gained by parallel chemical and physical studies of Ea and its deaminated and denatured derivatives and lead to the conclusion that the products described have definite form and structure.

In previous papers^{3,4} it was shown that the fraction B of partially deaminated egg albumin (Ea) soluble at the isoelectric point (i.e.p.), had

(1) Submitted by Paul H. Maurer in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the Faculty of Pure Science, Columbia University.

(2) Presented before the 34th Annual Meeting of the American Association of Immunologists, Atlantic City, N. J., April 17–21, 1950.

(3) P. H. Maurer and M. Heidelberger, *THIS JOURNAL*, **73**, 2070 (1951).

(4) P. H. Maurer and M. Heidelberger, *ibid.* **73**, 2072 (1951).

many properties resembling those of native Ea. On the other hand, Fraction A, which was rendered insoluble at the i.e.p. during deamination and acquired many of the properties of denatured Ea (DnEa), nevertheless showed definite differences from Ea denatured, for example, by acid.

These resemblances and differences are further illustrated in the accompanying quantitative immunochemical studies. These show both the wide applicability and the limitations of this technique.

Experimental

1. **Immune Sera.**—Antisera were prepared against Ea,⁵ acid DnEa,⁹ and fractions A and B of deaminated lot 4, by injection of rabbits intravenously with neutral suspensions of alum-precipitated protein containing 1.5 mg. of antigen per ml. Initial doses of 0.5–1.5 mg. were increased to 4 mg. during the first 2 weeks and to 8 mg. by the end of the course which consisted of 4 injections a week for 4 weeks. Bleedings were taken about a week after the last injection.

Antisera to Ea and 4B contained about 2.5 and 1.5 mg. antibody N per ml., respectively. On the other hand, antisera to DnEa and 4A were generally weak, containing about 0.12 and 0.25 mg. antibody N per ml., respectively, in accord with observations that denatured proteins are less antigenic than the native forms from which they are derived.^{8,7}

2. **Analytical Methods.**—Quantitative analyses in anti-4B sera were carried out as in the Ea-anti Ea system⁶ and were allowed to stand 48 hours at 0°. A few analyses were done at 37° for comparison. Analyses in the inhibition zone in anti-Ea and anti-4B sera were run at 37° for 1 hour and then placed in the ice-box for 4 days with stirring each day.⁵ Analyses in anti-4A sera were run as with anti-DnEa sera,⁹ but no difference could be observed in total N precipitated whether Fraction A was diluted with 0.5% NaCl solution, as was always done in the case of DnEa⁹ or with 0.9% NaCl, as is usual. Accurately measured solutions of antigen and serum were mixed and allowed to stand at 37° for 3 hr. The precipitates were centrifuged off at room temperature and washed twice at 0° with 0.9% NaCl solution. All washings were spun in a refrigerated centrifuge. In the case of the specific precipitates with DnEa as antigen 0.5% NaCl solutions containing 1 ml. of 1% saponin per 100 ml. were used as wash fluid. N in the precipitates was determined by the Markham modification of the micro-Kjeldahl procedure.⁸ Cross reactions were generally run at the two concentrations indicated in the tables and figures.

Results and Discussion

1. Comparisons in Anti-Ea and Anti-4B Sera.

—Homologous and cross reactions of Ea and fraction B, whether in the oxidized (–S–S–) or reduced (–SH) forms, with calibrated anti-Ea (Fig. 1) and calibrated anti-B sera (Fig. 2) were indistinguishable up to the region of moderate antigen excess. These data furnish a rare example of the limitations of quantitative immunochemical techniques, for Ea and Fraction B were obviously different in their electrophoretic mobilities,⁴ –NH₂ content, and other properties. However, when determinations of specifically precipitable N were made with large quantities of antigen far out in the inhibition zone, the B fraction always precipitated more N, that is, inhibited less. According to Cohn, Wetter and Deutsch⁹ this might indicate a slight impurity in the B fraction. Along these lines, it is possible that a trace of Fraction A, conalbumin or other constituent of egg white not detectable by other methods had become more concentrated in the B fraction than in the original Ea used.

The data obtained indicate that in the native Ea-anti-Ea and B fraction-anti-B systems sero-

(5) M. Heidelberger and F. E. Kendall, *J. Exptl. Med.*, **62**, 697 (1935).

(6) C. F. C. MacPherson and M. Heidelberger, *THIS JOURNAL*, **67**, 585 (1945).

(7) H. Wu, C. TenBroeck and C. P. Li, *Chinese J. Physiol.*, **1**, 277 (1927).

(8) R. Markham, *Biochem. J.*, **36**, 790 (1942); E. A. Kabat and M. M. Mayer, "Experimental Immunochemistry," C. C. Thomas, Springfield, Ill., 1948.

(9) M. Cohn, L. R. Wetter and H. F. Deutsch, *J. Immunol.*, **61**, 283 (1949).




Fig. 1.—Homologous and cross precipitation with anti-Ea serum FK2 (1 → 4). Key to chart: O, Ea; ●, Ea at 37°; ▽, 4B; ▴, 4B at 37°; ▾, 5B; ▼, 8B SS; □, 5A; ■, 6A; ◇, DnEa 101; ◆, HtDn 27.




Fig. 2.—Homologous and cross precipitation with anti-4B serum 979₁ (1 → 10). Key to chart: ▽, 4B; ▼, 4B at 37°; ▾, 3B; ▴, 5B; O, Ea; ●, Ea at 37°; ■, 4A.

logical specificity is unaffected by the presence or absence of roughly one-third of the amino groups or by the state of the –S– groups as –S–S– or –SH. This confirms the work of Blumenthal¹⁰ who found no difference between the –SH or –S–S– forms of Ea with anti-Ea sera. The urease-anti-urease¹¹ and ferritin-anti-ferritin¹² systems behave similarly.

Both acid DnEa and fraction A gave cross reactions with anti-4B and anti-Ea sera to the same slight degree, indicating that they are both denatured forms of Ea. This is also borne out by the cross reactions of A fractions with anti-acid DnEa sera discussed below.

2. **Comparisons in Anti-DnEa and Anti-A Sera.**—From the cross reactions of the A fractions in anti-acid DnEa sera (Fig. 3) and acid DnEa in anti-4A sera (Fig. 4) it is apparent that the two derivatives of Ea are different serologically although they are both denatured. It was shown previously that DnEa prepared by

(10) D. Blumenthal, *J. Biol. Chem.*, **113**, 433 (1936).

(11) L. Pillemer, E. E. Ecker, V. C. Myers and E. Muntwyler, *ibid.*, **123**, 365 (1938).

(12) A. Mazur, personal communication.

TABLE I

ADDITION OF INCREASING AMOUNTS OF Ea AND VARIOUS DEAMINATED AND DENATURED DERIVATIVES TO 1.0 ML. OF ANTI-Ea SERUM FK2 1 → 4 AT 0°

Ea N added, mg.	Total N pptd., mg.	Anti-body N by diff., mg.	Anti-body N: antigen N ratio	Supernatant tests	Prepn. added	Antigen N added, mg.	Total N pptd., mg.	Prepn. added	Antigen N added, mg.	Total N pptd., mg.
0.010	0.209	0.199	19.9	Excess antibody	4B	0.030	0.472	3A	0.030	0.068
.020	.355	.335	16.8	Excess antibody	4B	.051	.588	3A	.050	.086
.030	.466	.436	14.5	Excess antibody	4B ^a	.075	.644	4A	.027	.050
.060	.640	.580	9.7	Excess antibody	4B	.170	.543	4A	.047	.052
.074 ^a	.690	.618	8.1		4B	.500	.135	DnEa 101	.030	.086
				Trace antibody;						
				0.004 mg. Ea	5B	.030	.460	DnEa 101	.050	.100
.080 ^b	.694			Excess Ea	5B	.050	.606	Ht Dn 27	.034	.064
.100	.610			Excess Ea	5B ^a	.075	.676	Ht Dn 27	.068	.092
.174	.304			Excess Ea	5B	.158	.622			
.464	.055				5B	.520	.117			
					8B (-SH)	.032	.482			
					8B (-SH)	.065	.646			
					8B (-S-S-)	.030	.464	Similar values obtained with		
					8B (-S-S-)	.060	.640	5A, 6A, 8A (-S-S-), 8A		
								Similar values obtained with		
								(-SH)		
								3B and 6B		

^a Reaction run at 37° for 1 hr. ^b 0.076 mg. precipitated by antibody.

TABLE II

ADDITION OF INCREASING AMOUNTS OF B, Ea AND A FRACTIONS TO 1.0 ML. OF ANTI-4B SERUM 979₁ (1 → 10) AT 0°

4B N added, mg.	Total N pptd., mg.	Antibody N by diff., mg.	Antibody N: antigen N ratio	Supernatant tests	Prepn. added	Antigen N added, mg.	Total N pptd., mg.	Prepn. added	Antigen N added, mg.	Total N pptd., mg.
0.0033	0.047	0.044	13.3	Excess antibody	Ea	0.0116	0.130	3A	0.0093	0.019
.005	.067	.062	12.4	Excess antibody	Ea	.0174	.162	3A	.016	.017
.010	.104	.094	9.4	Excess antibody	Ea ^b	.023	.169	4A	.009	.017
.015	.142	.127	8.5	Excess antibody	Ea	.046	.085	4A	.015	.017
.020 ^a	.164	.144	7.2	No antibody or 4B	3B	.0093	.107	5A	.008	.017
.025	.171	.146		Excess 4B	3B	.014	.139	5A	.015	.018
.050	.107			Excess 4B	5B	.0105	.116			
					5B ^b	.020	.163			
					5B	.050	.107			

^a Same values at 37°. ^b Run at 37°.

TABLE III

ADDITION OF INCREASING AMOUNTS OF ACID DnEa, Ea, AND ITS DEAMINATED AND DENATURED DERIVATIVES TO 1.0 ML. OF POOLED ANTI-ACID DnEa SERA 795₁ AND 969₁ (1 → 2) AT 37°

DnEa N added, mg.	Total N pptd., mg.	Anti-body N by diff., mg.	Anti-body N: antigen N ratio	Supernatant tests	Prepn. added	Antigen N added, mg.	Total N pptd., mg.	Prepn. added	Antigen N added, mg.	Total N pptd., mg.
0.0055	0.059	0.053	9.6	Excess antibody	Ea	0.070	0.002	4A	0.021	0.063
.023	.088	.065	2.8	Excess antibody	Ea	.124	.003	4A	.053	.071
.057	.112			Excess antibody, excess DnEa	6B	.026	.005	6A	.0216	.070
.086	.116			Excess DnEa	6B	.069	.006	6A	.065	.079
					6B Dn	.022	.086	6A Dn	.024	.070
					6B Dn	.066	.095	6A Dn	.064	.084
					DnEa 105	.042	.094	8A	.025	.062
					Deam -SH	.085	.099	8A	.063	.036
					DnEa 105	.0423	.094	8A Dn	.025	.069
					Deam -S-S-	.085	.099	8A Dn	.064	.055
					Ea FNA	.069	.074 ^a	8A FNA	.068	.069 ^a

^a Single determination only. 3A, 5A and 5A Dn behaved like 4A, 6A and 6A Dn. 8B Dn was similar to 6B Dn. DnEa 106 Deam -SH and -S-S- similar to the 105 preparations.

heat, acid and alkali were all closely related immunologically through the region of antibody excess and into the equivalence zone.⁶ The type or the

degree of aggregation appeared to have no influence on the results except in the region of antigen excess, where quantitative differences could be

TABLE IV

ADDITION OF INCREASING AMOUNTS OF A, Ea AND ITS DEAMINATED AND DENATURED DERIVATIVES TO 1.0 ML. OF ANTI-4A SERUM 990₁ (1 → 2) AT 37°

4A N added, mg.	Total N pptd., mg.	Antibody N by diff., mg.	Anti-body N: anti-gen N ratio	Supernatant tests	Prepn. added	Antigen N added, mg.	Total N pptd., mg.	Prepn. added	Antigen N added, mg.	Total N pptd., mg.
0.0035	0.042	0.0385	11.0	Excess antibody	Ea	0.0046	0.004	5A	0.009	0.091
.0053	.061	.056	10.6	Excess antibody	Ea	.0184	.008	5A	.023	.136
.0106	.092	.081	7.6	Excess antibody	6B	.0068	.007	8A	.0125	.108
.016	.138	.122	7.6	Excess antibody	6B	.0168	.012	8A	.025	.150
.021	.155	.134	6.4	Trace antibody; trace 4A	8B Dn	.012	.051	8A Dn	.0125	.100
					8B Dn	.024	.080	8A Dn	.025	.146
.027	.147			Excess 4A	DnEa 105	.0086	.040	8A FNA	.0076	.066 ^a
					DnEa 105	.022	.082	8A FNA	.023	.144 ^a
								Ea FNA	.0075	.068 ^a
								Ea FNA	.0225	.143 ^a

^a Single determination only.


observed between various DnEa preparations. The A fractions however, differed from DnEa in not precipitating as much antibody from anti-DnEa sera even in the region of antibody excess, while a still greater deficit occurred in the region of antigen excess. Similar results were obtained with cross reactions of acid DnEa with an anti-4A serum. The serological specificity of the ADn fractions in anti-4A and anti-acid DnEa sera differed little from that of A itself. Both Ea FNA and 8A FNA in their reduced (-SH) and oxidized (-S-S-) forms reacted serologically as normal A fractions.

The immunochemical results confirm the physical and chemical data showing that the denatured protein arrived at as a result of deamination is different from the other denatured preparations and so furnish another example of the utility of immunochemistry in the study of proteins.¹³ The immunological evidence indicates not only that the processes characteristic of acid denaturation fail to reach completion in fraction A but also that the molecule may have unfolded into so

stable a configuration that further acid treatment causes little or no change in structure. The new configuration arrived at during the unfolding of the protein molecule is much more resistant than Ea or fraction B to acid denaturation and is also more stable than acid DnEa to aggregating influences.

The BDn preparations had a smaller particle weight than acid DnEa⁴ and reacted toward antisera like DnEa of a low degree of aggregation. Accordingly, BDn was indistinguishable from DnEa in the region of antibody excess in an anti-DnEa serum, while in the region of excess antigen BDn precipitated less total N than did DnEa. In anti-A serum BDn behaved like acid DnEa with no observable influence of the state of aggregation.


Both the -S-S- and -SH forms of deaminated DnEa showed definite differences from DnEa in anti-DnEa sera in that they precipitated somewhat less N. However, in anti-4A serum obtained after a second course of injections the DnEa Deam behaved like DnEa. Ea and fraction B cross reacted with anti-DnEa and anti-4A sera to a very slight degree.¹⁴



Mg. antigen N added per ml. of serum dilution.

Fig. 3.—Homologous and cross precipitation in pooled anti acid DnEa sera 795₁ and 969₁ (1 → 2) Key to chart: ◇, DnEa 101; ◊, DnEa 105; ◄, DnEa 105 Deam SH; ◂, DnEa 106; ◃, DnEa 106 Deam SH; ◆, DnEa 106 Deam SS; □, 6A; ×, 6A Dn; ▼, 6B; +, 6B Dn; ○, Ea; ●, Ea FNA; ▣, 8A FNA.

(13) E. A. Kabat, *J. Immunol.*, **47**, 513 (1943).



Mg. antigen N added per ml. of serum dilution.

Fig. 4.—Homologous and cross precipitation with anti-4A serum 990₁ (1 → 2): Key to chart: □, 4A; ■, 8A; ▣, 8A FNA; ○, Ea; ●, EA FNA; ◊, DnEa 105; +, 8B Dn; ×, 8A Dn; ▽, 6B.

(14) Cf. also C. F. C. MacPherson and M. Heidelberger, *Proc. Soc. Exptl. Biol. Med.*, **43**, 646 (1940).

The definite physical and chemical differences⁴ as well as the antigenicity and characteristic specificity of the various denatured forms of Ea (also ref. 6) studied in this Laboratory show a reproducibility, degree of organization and specificity indicating that they have not reached the final step in the denatured state characterized as a completely random one¹⁵ devoid of any specific

(15) W. T. Astbury, S. Dickinson and K. Bailey, *Biochem. J.*, **29**, 2351 (1935).

structure. The present studies therefore corroborate the concept that various degrees of denaturation exist¹⁶ and suggest that denaturation may take place by more than one pathway to yield different end products.

(16) H. P. Lundgren and J. W. Williams, *J. Phys. Chem.*, **43**, 989 (1939); H. P. Lundgren, *J. Biol. Chem.*, **138**, 293 (1941); H. Neurath, J. P. Greenstein, F. W. Putnam and J. O. Erickson, *Chem. Revs.*, **34**, 157 (1944).

NEW YORK 32, N. Y.

RECEIVED JULY 11, 1950

[CONTRIBUTION FROM THE CHEMICAL LABORATORY OF HARVARD UNIVERSITY, DEPARTMENT OF SURGERY OF BETH ISRAEL HOSPITAL AND HARVARD MEDICAL SCHOOL]

Synthesis of Naphthyl Carbonate Derivatives of Amino Acids as Chromogenic Substrates for Carboxypeptidase¹

BY GEORGE WOLF AND ARNOLD M. SELIGMAN

The synthesis of carbonaphthoxyphenylalanine is described. Since the peptide is colorless, slightly soluble in aqueous solution, moderately stable at pH 7.8, unattacked by esterase and lipase (preliminary observation) and hydrolyzed by crystalline carboxypeptidase or by pancreatic tissue which has been subjected to tryptic digestion, it appears to possess properties on which to base a method for the colorimetric demonstration of carboxypeptidase.

The structural requirements of substrates susceptible to enzymatic hydrolysis by carboxypeptidase have been defined.² These are a phenylalanine or tyrosine residue with a free carboxyl group (Ia), a peptide link which is hydrolyzed by the enzyme (Ib), and acyl group (I; RCO), which may consist of a peptide chain, a benzoylglycyl group (I; R = C₆H₅CONHCH₂-), carbobenzoxy residue (I; R = C₆H₅CH₂O-), chloroacetyl group (I; R = ClCH₂-) or acetyl group (I; R = CH₃-).

In order to make possible the development of highly colored azo dyes from the hydrolysis product of the substrate for the colorimetric determination or histochemical demonstration of enzymatic activity, analogous compounds with a carbonaphthoxy group (I; R = C₁₀H₇O-) were prepared. Following enzymatic hydrolysis, naphthyl carbonate would be expected to lose CO₂ to form β-naphthol which could be converted to an azo dye as in methods developed previously for a variety of enzymes.³⁻⁹

On the basis of earlier studies² with synthetic substrates, it was expected that carbonaphthoxyphenylalanine (VIII) would provide sufficient specificity for demonstrating carboxypeptidase. In addition to the diester, dinaphthyl carbonate

(1) This investigation was supported by a research grant from the National Cancer Institute of the National Institutes of Health, Public Health Service, (in part) by a grant from the American Cancer Society (Massachusetts Division), and (in part) by an institutional grant to Harvard University from the American Cancer Society.

(2) H. Neurath and G. W. Schwert, *Chem. Revs.*, **46**, 69 (1950).

(3) M. L. Menten, J. Junge and M. H. Green, *J. Biol. Chem.*, **153**, 471 (1944).

(4) L. H. Manheimer and A. M. Seligman, *J. Nat. Cancer Inst.*, **9**, 181 (1948).

(5) M. M. Nachlas and A. M. Seligman, *ibid.*, **9**, 415 (1949).

(6) M. M. Nachlas and A. M. Seligman, *Anat. Record*, **105**, 677 (1949).

(7) M. M. Nachlas and A. M. Seligman, *J. Biol. Chem.*, **181**, 343 (1949).

(8) A. M. Seligman, M. M. Nachlas, L. H. Manheimer, O. M. Friedman and G. Wolf, *Ann. Surg.*, **130**, 333 (1949).

(9) A. M. Seligman and M. M. Nachlas, *J. Clin. Invest.*, **29**, 31 (1950).

